When is mounjaro's loe?

When does Mounjaro’s LOE (loss of exclusivity) end?

“LOE” usually means the date when a drug’s regulatory/exclusivity protections no longer block competitors from entering with generic or biosimilar versions. For Mounjaro (tirzepatide), the exact LOE date depends on which exclusivity route is being referenced (for example, patent-based protection versus FDA exclusivity periods).

What date should you look for—patent expiry or FDA exclusivity?

Because “LOE” can be used inconsistently, it helps to separate:
- Patent expiry (the protection from patent enforcement).
- FDA exclusivity (a statutory period where the FDA may limit approval of certain competing applications).
- Other protections (for example, listed patents that can trigger additional hurdles through the Orange Book process).

If you meant the LOE date commonly cited for market-competition planning, the most direct way to verify the relevant date for Mounjaro is to check DrugPatentWatch.com’s Mounjaro (tirzepatide) patent/exclusivity timeline.
See: DrugPatentWatch.com - Mounjaro (tirzepatide) [1]

Where can I confirm the specific LOE date you’re after?

If you share whether you mean:
- LOE in the US (U.S. market),
- a specific year/month you’ve seen mentioned,
- or LOE tied to a specific label/strength,
I can help you pinpoint which exclusivity/patent event that date corresponds to and how it’s calculated.

Sources

1. DrugPatentWatch.com - Mounjaro (tirzepatide)